VYYRF - Voyageur Pharmaceuticals Ltd. Announces Second Health Canada Approval and Issuance of Product License for HDXBa; Radiographic Barium Contrast
(TheNewswire)
Calgary, Alberta - TheNewswire - February 16,2021 - Voyageur Pharmaceuticals Ltd. ( TSX V : VM ) ( OTC : VYYRF) (the "Company"or "Voyageur") is pleased to announcethat it has received approval from Health Canada for its secondproduct, HDX Ba . HDX Ba is a bariumradiographic contrast powder for suspension that is specificallyformulated for Fluoroscopy barium X-Ray procedures and can also beused for CT Scans. This approval authorizes the sale ofHDX Ba for use in radiologyprocedures in Canada. HDX Ba is specifically designed for X-Ray procedures of the entireupper and lower GI tract, including the stomach and duodenum for usein both adults and pediatric patients.
This represents the second Health Canada licenceapproval for Voyageur, which has three additional barium radiographiccontrast products currently under review by Health Canada, withapprovals expected forthcoming.
“This approval is another key milestone to allow ourcompany to transition to manufacturing and production” reports BrentWillis, Voyageur’s CEO.
Voyageur has a strategic plan to advance through thestart-up phase of formulating, final testing of product and thenmanufacturing. This is expected to lead to full productionmanufacturing, sales and distribution of barium contrast productsnationally in the near term.
About Voyageur
Voyageur Pharmaceuticals Ltd. is Canadian publiccompany listed on the TSX Venture Exchange under the trading symbolVM. Voyageur is focused on the development of barite and iodine,Active Pharmaceutical Ingredient (API) minerals. The near-term focusis developing barium and iodine radio-contrast pharmaceuticalproducts.
Voyageur’s goal is to initially generate the positivecash flow from operations using third party GMP pharmaceuticalmanufacturers in Canada and in India. Ultimately, Voyageur has plansto build all the required infrastructure to become 100%self-sufficient with all manufacturing.
Voyageur owns a 100% interest in three barium sulfate(barite) projects including two properties suitable in grade for theindustrial barite marketplace, with interests in a high-grade iodine,lithium & bromine brine project located in Utah, USA.
Voyageur is moving forward with its business plan ofbecoming the only fully-integrated company in the radiocontrastmedical field, by controlling all primary input costs under the mottoof:
"From theEarth to the Bottle"
www.voyageurpharmaceuticals.ca
For Further Media Information or toset up an interview, please contact:
Brent Willis
President & CEO
Ron Love
CFO
T 403.818.6086
Forward Looking Information
This news release may contain certainforward-looking information and statements, including withoutlimitation, statements pertaining to timing for manufacturing andsales of HDXBa and the Company's ability to obtain necessary approvals from Health Canada for thefour additional barium radiographic contrast products. All statementsincluded herein, other than statements of historical fact, areforward-looking information and such information involves variousrisks and uncertainties. There can be no assurance that suchinformation will prove to be accurate, and actual results and futureevents could differ materially from those anticipated in suchinformation. A description of assumptions used to develop suchforward-looking information and a description of risk factors that maycause actual results to differ materially from forward-lookinginformation can be found in the Company's disclosure documents on theSEDAR website at www.sedar.com . Voyageur does not undertake to update any forward-lookinginformation except in accordance with applicable securitieslaws.
Reader Advisory
Neither the TSXV nor its RegulationServices Provider (as that term is defined in the policies of theTSXV) accepts responsibility for the adequacy or accuracy of this newsrelease.
NOT FOR DISTRIBUTION TO THE U.S.NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Copyright (c) 2021 TheNewswire - All rights reserved.